Management of antiretroviral drug therapy in human immunodeficiency virus infection.

about

Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.

P2860

Q35369891-F16F6DF6-127D-42AB-8654-A9F12363DDFF

P2860

Management of antiretroviral drug therapy in human immunodeficiency virus infection.

Item

http://www.wikidata.org/entity/Q40626125

description

1994 nî lūn-bûn

@nan

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

1994年论文

@zh

1994年论文

@zh-cn

name

Management of antiretroviral drug therapy in human immunodeficiency virus infection.

@en

type

Item

label

Management of antiretroviral drug therapy in human immunodeficiency virus infection.

@en

prefLabel

Management of antiretroviral drug therapy in human immunodeficiency virus infection.

@en

P1476

Management of antiretroviral drug therapy in human immunodeficiency virus infection.

@en

P2093

Stretcher B

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction

A randomized trial of reduced doses of azidothymidine in Japanese patients with human immunodeficiency virus type 1 infection

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo

P304

169-196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10408369409084676

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

1994-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7917008

http://www.w3.org/2001/XMLSchema#string

Management of antiretroviral drug therapy in human immunodeficiency virus infection.

about

P2860

P2860

Management of antiretroviral drug therapy in human immunodeficiency virus infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698